Myeloperoxidase modulates human platelet aggregation via actin cytoskeleton reorganization and store-operated calcium entry

Abstract

SummaryMyeloperoxidase (MPO) is a heme-containing enzyme released from activated leukocytes into the extracellular space during inflammation. Its main function is the production of hypohalous acids that are potent oxidants. MPO can also modulate cell signaling and inflammatory responses independently of its enzymatic activity. Because MPO is regarded as an important risk factor for cardiovascular diseases associated with increased platelet activity, we studied the effects of MPO on human platelet functional properties. Laser scanning confocal microscopy was used to reveal carbohydrate-independent MPO binding to human platelet membrane. Adding MPO to platelets did not activate their aggregation under basal conditions (without agonist). In contrast, MPO augmented agonist-induced platelet aggregation, which was not prevented by MPO enzymatic activity inhibitors. It was found that exposure of platelets to MPO leads to actin cytoskeleton reorganization and an increase in their elasticity. Furthermore, MPO evoked a rise in cytosolic Ca2+ through enhancement of store-operated Ca2+ entry (SOCE). Together, these findings indicate that MPO is not a direct agonist but rather a mediator that binds to human platelets, induces actin cytoskeleton reorganization and affects the mechanical stiffness of human platelets, resulting in potentiating SOCE and agonist-induced human platelet aggregation. Therefore, an increased activity of platelets in vascular disease can, at least partly, be provided by MPO elevated concentrations.

Ex vivoobservation of granulocyte activity during thrombus formation

“…However, the influence of leukocytes on platelet activation and thrombus growth is under-investigated. Here, in line with previous studies (25,(38)(39)(40)(41)(42)(43), granulocytes' activation resulted in granulocyte shape and velocity changes (Fig. 3G-I), as well as in the changes in thrombus area (Fig S4A).…”

Platelets Proteomic Profiles of Acute Ischemic Stroke Patients

“…Furthermore, MPO is known as a heme protein and cellular catalytic enzyme which is released form monocyte and neutrophils. It has been shown that MPO binds to human platelets and triggers platelet activation and aggregation via releasing Ca 2+ from platelets’ intracellular stores [ 62 ]. In addition, ALOX12 is a known arachidonate 12-lipoxygenase and its role in platelets functions is not well understood.…”

The Ontogeny of a Neutrophil: Mechanisms of Granulopoiesis and Homeostasis

“…MPO is a cationic glycoprotein that can also bind to the surface of neutrophils (123) and platelets (124) via electrostatic carbohydrate-dependent mechanisms, thereby triggering proinflammatory functional activities (125). The priming and activation of neutrophils by inflammatory mediators, such as Toll-like receptor (TLR) ligands (126), GM-CSF (127), TNF-␣, and Ig/Fc receptor-mediated signaling (128), can liberate MPO extracellularly by both degranulation and cell death pathways, including apoptosis and necrosis (108).…”